A fibrin coating method of polypropylene meshes enables the adhesion of menstrual blood-derived mesenchymal stromal cells: a new delivery strategy for stem cell-based therapies

• Autor(a) principal: Marinaro, Federica
• Data de Publicação: 2021
• Outros Autores: Silva, Joana Maria Marques, Barros, Alexandre António Antunes, Aroso, Ivo Manuel Ascensão, Gómez-Blanco, Juan C., Jardin, Isaac, Lopez, Jose J., Pulido, María, Pedro, María Ángeles de, Reis, R. L., Sánchez-Margallo, Francisco Miguel, Casado, Javier G., López, Esther
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: https://hdl.handle.net/1822/77927
• topic: Surgical mesh; Fibrin sealant; Coating; Fibrin; Cell therapy; Menstrual blood-derived stromal cell; menstrual blood-derived stromal cells; Science & Technology

Polypropylene (PP) mesh is well-known as a gold standard of all prosthetic materials of choice for the reinforcement of soft tissues in case of hernia, organ prolapse, and urinary incontinence. The adverse effects that follow surgical mesh implantation remain an unmet medical challenge. Herein, it is outlined a new approach to allow viability and adhesion of human menstrual blood-derived mesenchymal stromal cells (MenSCs) on PP surgical meshes. A multilayered fibrin coating, based on fibrinogen and thrombin from a commercial fibrin sealant, was optimized to guarantee a homogeneous and stratified film on PP mesh. MenSCs were seeded on the optimized fibrin-coated meshes and their adhesion, viability, phenotype, gene expression, and immunomodulatory capacity were fully evaluated. This coating guaranteed MenSC viability, adhesion and did not trigger any change in their stemness and inflammatory profile. Additionally, MenSCs seeded on fibrin-coated meshes significantly decreased CD4+ and CD8+ T cell proliferation, compared to in vitro stimulated lymphocytes (<i>p</i> < 0.0001). Hence, the proposed fibrin coating for PP surgical meshes may allow the local administration of stromal cells and the reduction of the exacerbated inflammatory response following mesh implantation surgery. Reproducible and easy to adapt to other cell types, this method undoubtedly requires a multidisciplinary and translational approach to be improved for future clinical uses.